Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Tumori ; 104(4): 300-306, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29714667

RESUMO

AIMS AND BACKGROUND: The treatment of glomus jugulare tumors (GJT) remains controversial due to high morbidity. Historically, these tumors have primarily been managed surgically. The purpose of this retrospective review was to assess the tumor and clinical control rates as well as long-term toxicity of GJT treated with radiosurgery. METHODS: Between 1993 and 2014, 30 patients with GJT (31 tumors) were managed with radiosurgery. Twenty-one patients were female and the median age was 59 years. Twenty-eight patients (93%) were treated with radiosurgery, typically at 14 Gy ( n = 26), and 2 patients (7%) with stereotactic radiosurgery. Sixteen cases (52%) had undergone prior surgery. RESULTS: The mean follow-up was 4.6 years (range 1.5-12). Crude overall survival, tumor control, clinical control, and long-term grade 1 toxicity rates were 97%, 97%, 97%, and 13% (4/30), respectively. No statistically significant risk factor was associated with lower tumor control in our series. Univariate analysis showed a statistically significant association between patients having 1 cranial nerve (CN) involvement before radiosurgery and a higher risk of lack of improvement of symptoms (odds ratio 5.24, 95% confidence interval 1.06-25.97, p = .043). CONCLUSIONS: Radiosurgery is an effective and safe treatment modality for GJT. Patients having 1 CN involvement before radiosurgery show a higher risk of lack of improvement of symptoms.


Assuntos
Tumor do Glomo Jugular/radioterapia , Tumor do Glomo Jugular/cirurgia , Radiocirurgia , Adolescente , Adulto , Idoso , Feminino , Tumor do Glomo Jugular/diagnóstico por imagem , Tumor do Glomo Jugular/patologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
2.
Neurocir. - Soc. Luso-Esp. Neurocir ; 23(6): 234-243, nov.-dic. 2012.
Artigo em Espanhol | IBECS | ID: ibc-111354

RESUMO

Objetivo Las malformaciones arteriovenosas (MAV) del tronco cerebral conllevan un alto riesgo de hemorragia recurrente y de morbimortalidad. Las opciones de tratamiento son limitadas y principalmente asientan sobre la radiocirugía estereotáctica. Estudiamos los resultados de nuestra serie de MAV de tronco tratadas con acelerador lineal (LINAC) con seguimiento a largo plazo. Métodos Se analizan retrospectivamente los datos clínicos y radiológicos de 41 pacientes consecutivos con MAV de tronco tratadas mediante radiocirugía con acelerador lineal de 6MV entre 1992 y 2010. Comprendían 25 lesiones en mesencéfalo, 14 en protuberancia, una en bulbo y otra bulboprotuberancial. Se analizan los resultados del tratamiento en cuanto a (..) (AU)


Assuntos
Humanos , Malformações Arteriovenosas Intracranianas/cirurgia , Tronco Encefálico/cirurgia , Radiocirurgia/métodos , Aceleradores de Partículas , Perda Sanguínea Cirúrgica/prevenção & controle , Hemorragias Intracranianas/complicações , Estudos Retrospectivos
3.
Neurocirugia (Astur) ; 23(6): 234-43, 2012 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-22954619

RESUMO

OBJECTIVE: Arteriovenous malformations (AVM) in the brainstem carry a high risk of recurrent haemorrhage, mortality and morbidity. Treatment options are limited and mainly based on stereotactic radiosurgery. We studied the results of our series of brainstem AVM treated with linear accelerator (LINAC) and with a long-term follow-up. METHODS: We retrospectively analysed the clinical and radiological data of 41 consecutive patients with brainstem AVM treated by radiosurgery with a 6MV linear accelerator between 1992 and 2010. Twenty five lesions were located in the mesencephalon, 14 in the pons, one in the medulla oblongata and one was bulbopontine. We analysed the treatment results in relation to survival, rate of radiological obliteration, rebleeding, and treatment toxicity. RESULTS: The obliteration rate confirmed by angiography/MRA was 59.5% on 38 controlled patients. The mean follow-up period was 61 months (range: 6.7-178) and the margin dose was 14Gy in most treatments. Up to 39% of patients received more than one radiosurgery procedure to achieve closure of the malformation. No statistical correlation was found with the margin dose, presence of pretreatment haemorrhage, nidus diameter or score on the Pollock-Flickinger grading system. The annual haemorrhage rate after radiosurgery was 3.2%. Three patients died from rebleeding and actuarial survival rate was 88% at 5 and 10 years after treatment. Four patients suffered new transient neurological deficits due to toxicity, and only one presented a permanent deficit (2.6%). CONCLUSIONS: Nidus obliteration in brainstem AVM must be achieved according to three main criteria: maximum obliteration rate forced by the high rate of rebleeding, minimal morbidity given its critical location, and the greatest possible accuracy. Stereotactic radiosurgery with our moderate-dose protocol, which we believe achieved these three premises, may become an elective therapeutic modality for these patients.


Assuntos
Malformações Arteriovenosas Intracranianas , Radiocirurgia , Tronco Encefálico , Angiografia Cerebral , Humanos , Resultado do Tratamento
4.
Stereotact Funct Neurosurg ; 89(4): 220-5, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21613807

RESUMO

BACKGROUND: Stereotactic radiosurgery (SRS) is one option for treatment of trigeminal neuralgia, after unsuccessful conservative approaches. OBJECTIVES: The objective of this study was to retrospectively evaluate our institutional results in the management of patients with idiopathic trigeminal neuralgia treated with linear accelerator SRS. METHODS: Fifty-two patients were treated between January 1998 and December 2009 and were followed for more than 6 months (median: 26.6 months). Forty-seven patients (90%) had undergone previous surgery before SRS. The target dose ranged from 50 to 80 Gy. RESULTS: After SRS, 9 patients presented complete remission of the pain, and 21 were pain free but still under medication. Eleven patients reported a relief of more than 50% in crisis frequency. In 9 patients, no significant improvements were seen, and 2 presented an exacerbation of the pain. After an average period of 20 months, 15 patients reported pain recurrence. Results were better in patients older than 60 years (p = 0.019). Nineteen patients presented facial numbness after SRS, with a trend toward favorable treatment response (p = 0.06). CONCLUSION: SRS is an effective alternative to the treatment of essential trigeminal neuralgia, with long-lasting pain relief in more than 50% of the patients. Better results were seen with patients aged more than 60 years.


Assuntos
Radiocirurgia/instrumentação , Neuralgia do Trigêmeo/cirurgia , Adulto , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Resultado do Tratamento
5.
Int J Radiat Oncol Biol Phys ; 81(5): 1436-41, 2011 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-20971572

RESUMO

PURPOSE: Patients with cavernous sinus meningiomas (CSM) have an elevated risk of surgical morbidity and mortality. Recurrence is often observed after partial resection. Stereotactic radiosurgery (SRS), either alone or combined with surgery, represents an important advance in CSM management, but long-term results are lacking. METHODS AND MATERIALS: A total of 88 CSM patients, treated from January 1991 to December 2005, were retrospectively reviewed. The mean follow-up was 86.8 months (range, 17.1-179.4 months). Among the patients, 22 were followed for more than 10 years. There was a female predominance (84.1%). The age varied from 16 to 90 years (mean, 51.6). In all, 47 patients (53.4%) received SRS alone, and 41 patients (46.6%) had undergone surgery before SRS. A dose of 14 Gy was prescribed to isodose curves from 50% to 90%. In 25 patients (28.4%), as a result of the proximity to organs at risk, the prescribed dose did not completely cover the target. RESULTS: After SRS, 65 (73.8%) patients presented with tumor volume reduction; 14 (15.9%) remained stable, and 9 (10.2%) had tumor progression. The progression-free survival was 92.5% at 5 years, and 82.5% at 10 years. Age, sex, maximal diameter of the treated tumor, previous surgery, and complete target coverage did not show significant associations with prognosis. Among the 88 treated patients, 17 experienced morbidity that was related to SRS, and 6 of these patients spontaneously recovered. CONCLUSIONS: SRS is an effective and safe treatment for CSM, feasible either in the primary or the postsurgical setting. Incomplete coverage of the target did not worsen outcomes. More than 80% of the patients remained free of disease progression during long-term follow-up.


Assuntos
Seio Cavernoso/cirurgia , Neoplasias Meníngeas/cirurgia , Meningioma/cirurgia , Radiocirurgia/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Seio Cavernoso/patologia , Intervalo Livre de Doença , Feminino , Seguimentos , Humanos , Masculino , Neoplasias Meníngeas/mortalidade , Neoplasias Meníngeas/patologia , Meningioma/mortalidade , Meningioma/patologia , Pessoa de Meia-Idade , Dosagem Radioterapêutica , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...